Author:
Campion SN.,Potter DM.,Bowman CJ.,Catlin NR.,Davis S.,Millard C.,Nowland WS.,Stethem CM.,Hollingshead BD.,Radi ZA.,Coder PS.,Cappon GD.
Reference24 articles.
1. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis;Meyer;J. Inflamm. (Lond. ),2010
2. Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses;Collinge;Regul. Toxicol. Pharm.,2018
3. Jakafi (ruxolitinib) [United States Package Insert]. 2021, Incyte Corporation, Wilmington, DE.
4. Pharmaceuticals and Medical Devices Agency (PMDA) Review Report for Olumiant (baricitinib). 2021 [cited 2022 20 Apr 2022]; Available from: 〈https://www.pmda.go.jp/files/000243207.pdf〉.
5. Cibinqo (abrocitinib) [United States Package Insert]. 2022, Pfizer, New York, NY.